Reactions 1680, p76 - 2 Dec 2017 Telogen effluvium: case report A 49-year-old woman developed telogen effluvium during treatment with lanreotide and cabergoline [routes and outcome not stated; not all dosages stated]. The woman, who had a history of acromegaly, was started on lanreotide autogel 120mg every 56 days. She also had a nd history of pituitary adenoma. Four days after the 2 dose of lanreotide, she observed a progressive diffuse scalp hair loss. All other causes of alopecia were ruled out. Her examination showed a non-scarring diffuse hair loss affecting the scalp globally, suggestive of telogen effluvium. Eventually, the intensity of hair loss increased. The woman also experienced psychological disturbances related to her new appearance. Therefore, lanreotide treatment was discontinued. Five months after the discontinuation of lanreotide, hair loss improved significantly. Later, she was started on cabergoline in increasing doses due to active acromegaly and showed a slow decrease in insulin- like growth factor-1 (IGF-1) and growth hormone levels. Eighteen months after the initiation of cabergoline, a complete biochemical response was achieved. However, hair loss reoccurred coinciding with the increase in cabergoline dose and was not as severe as in case of lanreotide treatment. Author comment: "Scalp hair loss is an underreported adverse event of somatostatin analogs therapy that in severe cases may require treatment withdrawal." We cannot rule out a direct effect of Lanreotide, because with cabergoline, we also observed a normalization of IGF-1 levels, and the degree of alopecia that the patient referred was not as severe as with Lanreotide." Alvarez-Escola C, et al. Severe scalp hair loss in a female patient with acromegaly treated with lanreotide autogel after unsuccessful surgery. Clinical Case Reports 3: 945-948, No. 11, Nov 2015. Available from: URL: http://doi.org/10.1002/ccr3.388 - Spain 803284474 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera